Last checked at 22 Feb 2023 21:50
Hikma accuses Amarin of suppressing generic versions of heart pill
Hikma claims Amarin used exclusive agreements with suppliers to frustrate generic rivals
*Read more
- Home
- Share Prices
- AQSE Share Prices
- Euronext
- Stock Screeners
- Share Chat
- FX
- News & RNS
- Events
- Media
- Trading Brokers
- Finance Tools
- Members
Latest Share Chat
Hikma Pharmaceuticals Share News (HIK)
HIK Share
Price
HIK Share
News
HIK Share
Chat
HIK Share
Trades1,487
HIK
Live RNS
HIK Share
Charts
HIK Level 2
Console
HIK Live
Share Price
HIK Broker
Ratings
HIK Directors
Deals
HIK Financial
Diary
HIK
Fundamentals
HIK Short
Positions
HIK
Media
Hikma Pharmaceuticals Information
Share Price Information for Hikma Pharmaceuticals (HIK)
Share Price is delayed by 15 minutes
Get Live Data
Share Price:
1,971.00
Bid:
1,971.00
Ask:
1,972.00
Change:
-29.00 (-1.45%)
Spread:
1.00 (0.051%)
Open:
2,008.00
High:
2,012.00
Low:
1,958.00
Prev. Close:
2,000.00
Last checked at -
Watchlists are a member only feature
Login to your account
Don't have an account? Click here to register.Hikma lifts full year revenue guidance
Mon, 08th Jul 2013 07:06
Hikma Pharmaceutical said all of its businesses have continued to perform well and overall it expects revenue to grow by around 17 per cent in 2013, up from previous guidance of around 13 per cent.Across its main businesses, generics continued to benefit from strong doxycycline sales. Given the strong performance of doxycycline, Hikma said it is raising its full year guidance for this business to revenue of around $200m with a reported operating margin of above 30%. Elsewhere its branded business remains on track to meet its current full year guidance of around 9% revenue growth or 11% in constant currency, with adjusted operating margin in line with 2012. Due to the timing of shipments, Branded revenue growth is expected to be stronger in the second half of the year, Hikma explained.Its injectables business has performed well since its last update in May, driven by strong performances in the US and Europe. Hikma said there has been strong demand from the MENA region, where it has won some key tenders. "We expect these tenders will drive MENA revenue growth in the second half of the year. We continue to expect the global injectables business to deliver low double digit revenue growth for the full year," the group said in a statement.Chief Executive Officer Said Darwazah commented: "We are performing well across all of our businesses and I am pleased to be able to raise our group guidance for the full year once again.""Overall, our diversified business model is positioning the group to deliver another strong year in 2013."
More News
16 Feb 2023 15:49
UK earnings, trading statements calendar - next 7 days
| Friday 17 February | |
| Allianz Technology Trust PLC | Full Year Results |
| Kingspan Group PLC | Full Year Results |
| NatWest Group PLC | Full Year Results |
| Pod Point Group Holdings PLC | Full Year Results |
| Segro PLC | Full Year Results |
| Monday 20 February | |
| Bank of Cyprus Holdings PLC | Full Year Results |
| Georgia Capital PLC | Full Year Results |
| Goldplat PLC | Full Year Results (TBC) |
| LungLife AI Inc | Full Year Results |
| Tristel PLC | Half Year Results |
| Wilmington PLC | Half Year Results |
| Tuesday 21 February | |
| Antofagasta PLC | Full Year Results |
| BHP Group Ltd | Half Year Results |
| Blancco Technology Group PLC | Half Year Results |
| Finsbury Food Group PLC | Half Year Results |
| HSBC Holdings PLC | Full Year Results |
| InterContinental Hotels Group PLC | Full Year Results |
| Safestore Holdings PLC | Trading Statement |
| Smith & Nephew PLC | Full Year Results |
| Springfield Properties PLC | Half Year Results |
| Sylvania Platinum Ltd | Half Year Results |
| Trifast PLC | Trading Statement |
| Wednesday 22 February | |
| Avingtrans PLC | Half Year Results |
| City of London Investment Group PLC | Half Year Results |
| Conduit Holdings Ltd | Full Year Results |
| Liberty Global PLC | Full Year Results |
| Lloyds Banking Group PLC | Full Year Results |
| Primary Health Properties PLC | Full Year Results |
| Renewables Infrastructure Group Ltd | Full Year Results |
| Rio Tinto PLC | Full Year Results |
| Synectics PLC | Full Year Results |
| TBC Bank Group PLC | Full Year Results |
| Transense Technologies PLC | Half Year Results |
| Thursday 23 February | |
| Anglo American PLC | Full Year Results |
| Arbuthnot Banking Group PLC | Trading Statement |
| BAE Systems PLC | Full Year Results |
| Bluefield Solar Income Fund Ltd | Half Year Results |
| Drax Group PLC | Full Year Results |
| Driver Group PLC | Full Year Results |
| Genus PLC | Half Year Results |
| Hays PLC | Half Year Results |
| Hikma Pharmaceuticals PLC | Full Year Results |
| Howden Joinery Group PLC | Full Year Results |
| Macfarlane Group PLC | Full Year Results |
| Made Tech Group PLC | Half Year Results |
| Mondi PLC | Full Year Results |
| Morgan Sindall Group PLC | Full Year Results |
| Pantheon International PLC | Half Year Results |
| Rolls-Royce Holdings PLC | Full Year Results |
| Serco Group PLC | Full Year Results |
| Spectris PLC | Full Year Results |
| Versarien PLC | Full Year Results |
| WPP PLC | Full Year Results |
| Copyright 2023 Alliance News Ltd. All Rights Reserved. |
25 Jan 2023 09:33
LONDON BROKER RATINGS: Goldman likes UK banks; HSBC cuts Dr Martens
(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning:
Read more18 Jan 2023 15:07
Director dealings: Hikma Pharmaceuticals director snaps up shares
(Sharecast News) - Hikma Pharmaceuticals revealed on Wednesday that non-executive director Deneen Vojta had acquired 1,000 ordinary shares in the FTSE 250-listed drugmaker.
Read more12 Jan 2023 17:55
Arecor transfers AT307 drug to Hikma for development, regains AT282
(Alliance News) - Arecor Therapeutics PLC on Thursday said it transferred development activities for the ready-to-use injectable medicine AT307 to Hikma Pharmaceuticals PLC, and regained rights on AT282 after a product portfolio review.
Read more3 Jan 2023 17:31
FTSE 100 ends first trading day of 2023 on upbeat note
FTSE 100 up 1.4%, FTSE 250 adds 1.5%
*Read more3 Jan 2023 09:25
Hikma launches version of Xyrem medicine in US for treating narcolepsy
(Alliance News) - Hikma Pharmaceuticals PLC on Tuesday said it launched an authorised generic version of the Xyrem sodium oxybate prescription medicine in the US for treating narcolepsy.
Read more3 Jan 2023 09:24
LONDON BROKER RATINGS: Citigroup cuts Wizz Air; Redburn likes CRH
(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning, Monday and late Friday:
Read more3 Jan 2023 09:03
LONDON MARKET OPEN: Stocks jump in first session of 2023
(Alliance News) - Stock prices in London made a strong start to the new year on Tuesday, despite weak Chinese data and the UK suffering a fresh wave of rail strikes.
Read more3 Jan 2023 07:58
LONDON BRIEFING: Stocks called higher; China factory sector shrinks
(Alliance News) - Stocks in London are expected to start a new year on the front foot on Tuesday, after a mixed session in Asia amid weak Chinese economic data.
Read more3 Jan 2023 07:46
Hikma launches generic narcolepsy solution in US
(Sharecast News) - Hikma Pharmaceuticals has launched an authorised generic version of Jazz Pharmaceuticals' 'Xyrem 1', or sodium oxybate oral solution, it announced on Tuesday.
Read more8 Dec 2022 09:48
LONDON BROKER RATINGS: JPMorgan cuts Travis Perkins; BofA likes IAG
(Alliance News) - The following London-listed shares received analyst recommendations Thursday morning:
Read more6 Dec 2022 10:48
RBC Capital Markets starts Hikma at 'outperform'
(Sharecast News) - RBC Capital Markets initiated coverage of Hikma Pharmaceuticals on Tuesday at 'outperform' with a 1,750p price target.
Read more6 Dec 2022 10:26
LONDON BROKER RATINGS: JPMorgan cuts Lloyds but raises Barclays
(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning:
Read more15 Nov 2022 12:10
Credit Suisse initiates coverage of Hikma at 'outperform'
(Sharecast News) - Credit Suisse has initiated coverage of Hikma Pharmaceuticals with an 'outperform' rating.
Read more